Real-world effectiveness of voxilaprevir/velpatasvir/sofosbuvir in patients following DAA failure

• Published in: JHEP reports Vol. 6; no. 3; p. 100994
• Main Authors: Graf, Christiana, D’Ambrosio, Roberta, Degasperi, Elisabetta, Paolucci, Stefania, Llaneras, Jordi, Vermehren, Johannes, Dultz, Georg, Peiffer, Kai-Henrik, Finkelmeier, Fabian, Herrmann, Eva, Zeuzem, Stefan, Buti, Maria, Lampertico, Pietro, Dietz, Julia, Sarrazin, Christoph
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 01.03.2024; Elsevier
• Subjects: DAA treatment failure; Gastroenterology and Hepatology; Hepatitis C virus; Re-treatment; Voxilaprevir/velpatasvir/sofosbuvir; PP; DAA; Voxilaprevir/velpatasvir/sofosbuvir; DAA treatment failure; G/P; RASs; EOT; SOF; GT; SVR; IFN; Hepatitis C virus; VEL; Re-treatment; CTP; VOX; LDV; per protocol; velpatasvir; Child-Turcotte-Pugh; sustained virological response; voxilaprevir; resistance-associated substitutions; interferon; genotype; ledipasvir; sofosbuvir; direct-acting antiviral; end of treatment; glecaprevir/pibrentasvir

Voxilaprevir/velpatasvir/sofosbuvir (VOX/VEL/SOF) is highly effective for re-treatment of direct-acting antiviral (DAA)-experienced patients with chronic HCV infection. In the present study, predictors of virologic treatment response were analyzed in an integrative analysis of three large real-world...